RxDoctor Payments Data

Kyle Bruyninckx, MD

Internal Medicine · Rayville, LANPI 1972770378

Payments from drug & device makers

$5,008in general payments, 2019–2025

Across 305 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$615
  • AbbVie$501
  • Pfizer$467
  • Novo Nordisk$446
  • GSK$406
  • Lilly USA, LLC$291
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,89798%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,008 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$432,674
Medicare patients
430
Services billed
14,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide599$665,423
MounjaroTirzepatide515$593,304
EliquisApixaban384$304,371
TrulicityDulaglutide193$211,046
RybelsusSemaglutide144$174,133
LinzessLinaclotide200$129,668
EntrestoSacubitril/Valsartan111$94,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$88,395
JardianceEmpagliflozin77$73,930
XareltoRivaroxaban64$50,521
JanuviaSitagliptin Phosphate39$41,287
XifaxanRifaximin11$34,850
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$31,735
FarxigaDapagliflozin Propanediol43$31,625
TrintellixVortioxetine Hydrobromide52$30,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$446$839,555743 claims
Lilly USA, LLCMounjaro, Trulicity$291$804,350708 claims
PfizerEliquis, Nurtec Odt$467$323,427405 claims
AbbVieLinzess, Vraylar, Ubrelvy$501$177,170229 claims
GSKTrelegy Ellipta, Breo Ellipta$406$107,345150 claims
Boehringer IngelheimJardiance, Tradjenta$66$99,339106 claims
NovartisEntresto$169$94,729111 claims
AstraZenecaBreztri Aerosphere, Farxiga$615$63,36082 claims
MerckJanuvia, Janumet$75$52,69553 claims
Johnson & JohnsonXarelto$77$50,52164 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$87$48,97529 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$35$30,68752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Rayville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →